Trial Profile

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talimogene laherparepvec (Primary) ; Granulocyte colony-stimulating factors
Indications Malignant melanoma
Focus Adverse reactions
Acronyms OPTIM-extension
Sponsors BioVex

Most Recent Events

08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
15 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to M.D. Anderson Cancer Center.
06 Mar 2013 Actual initiation date changed from Oct 2010 to 8 Feb 2012 as reported by Vanderbilt-Ingram Cancer Center.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com